IP Library Granted Patent US 8,883,840
Granted Patent B2
US 8,883,840 · App. 13/619,915 · Granted Nov 11, 2014

Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents

Inventors: Mikhail Chafeev (Burnaby, CA); Jianmin Fu (Coquitlam, CA); Jean-Jacques Cadieux (Burnaby, CA)
Assignee: Xenon Pharmaceuticals Inc.
A61K31/407C07D491/22C07D491/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,883,840
App. No.
13/619,915
Granted
Nov 11, 2014
Kind
B2
Abstract

This invention is directed to the (S)-enantiomer of the compound of formula (I): or a pharmaceutically acceptable solvate or prodrug thereof. This (S)-enantiomer is useful for the treatment of diseases or conditions, such as pain, which are ameliorated or alleviated by the modulation of voltage-gated sodium channels.

Claims (2)

1. A method of treating neuropathic pain or inflammatory pain associated with Na V 1.7 sodium channel activity in a mammal, wherein the method comprises administering to the mammal in need thereof an amount of the (S)-enantiomer of 1′-{[5-(trifluoromethyl)furan-2-yl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3′-indol]-2′(1′H)-one having the following formula (I-S):

wherein the amount administered is effective in inhibiting Na V 1.7 sodium channel activity.

Continuity (3)
Division 12825168 · Jun 28, 2010
Provisional Application 61221424 · Jun 29, 2009
Related Publication 20130072537A1 · Mar 21, 2013